Literature DB >> 2152924

Identification of the benzothiazepine-binding polypeptide of skeletal muscle calcium channels with (+)-cis-azidodiltiazem and anti-ligand antibodies.

J Striessnig1, F Scheffauer, J Mitterdorfer, M Schirmer, H Glossmann.   

Abstract

The purified dihydropyridine-sensitive calcium channel from skeletal muscle transverse tubules consists of several subunits, termed alpha 1, alpha 2, beta, gamma and delta. From its associated drug receptors, those for 1,4-dihydropyridines and phenylalkylamines have been shown previously by photoaffinity labeling to reside on the alpha 1 subunit. In the present study the arylazide photo-affinity ligand, (+)-cis-azidodiltiazem ((+)-cis-(2S,3S)-5-[2-(4- azidobenzoyl)aminoethyl]-2,3,4,5-tetrahydro-3-hydroxy-2-(4-methoxyphenyl )-4- oxo-1,5-benzothiazepine), and the respective tritiated derivative, (+)-cis-[3H]azidodiltiazem (45 Ci/mmol), were developed to identify directly the benzothiazepine binding subunit. (+)-cis-Azidodiltiazem binds competitively to the benzothiazepine receptor in rabbit skeletal muscle transverse tubule membranes. Upon ultraviolet irradiation of the (+)-cis-[3H]azidodiltiazem-purified calcium channel complex, the ligand photoincorporates exclusively into the alpha 1 subunit. Photoincorporation is protected by 100 microM (-)-desmethoxyverapamil and 100 microM (+)-cis-diltiazem. A polyclonal antiserum directed against (+)-cis-azidodiltiazem was employed to detect (+)-cis-azidodiltiazem immunoreactivity photoincorporated into the purified calcium channel complex, confirming the exclusive labeling of the alpha 1 subunit. Our data provide direct evidence that, together with the drug receptors for 1,4-dihydropyridines and phenylalkylamines, the benzothiazepine binding domain of skeletal muscle calcium channels is located on the alpha 1 subunit. We conclude that our anti-ligand antibodies could be used successfully to affinity purify the photolabeled proteolytic fragments of the alpha 1 subunit which are expected to form part of the benzothiazepine binding domain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2152924

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Targeted disruption of the voltage-dependent calcium channel alpha2/delta-1-subunit.

Authors:  Geraldine A Fuller-Bicer; Gyula Varadi; Sheryl E Koch; Masakazu Ishii; Ilona Bodi; Nijiat Kadeer; James N Muth; Gabor Mikala; Natalia N Petrashevskaya; Michael A Jordan; Sui-Po Zhang; Ning Qin; Christopher M Flores; Idit Isaacsohn; Maria Varadi; Yasuo Mori; W Keith Jones; Arnold Schwartz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

Review 2.  Molecular basis of drug interaction with L-type Ca2+ channels.

Authors:  J Mitterdorfer; M Grabner; R L Kraus; S Hering; H Prinz; H Glossmann; J Striessnig
Journal:  J Bioenerg Biomembr       Date:  1998-08       Impact factor: 2.945

3.  A 75-kDa polypeptide, located primarily at the plasma membrane of carrot cell-suspension cultures, is photoaffinity labeled by the calcium channel blocker LU 49888.

Authors:  P Thuleau; A Graziana; H Canut; R Ranjeva
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12-15       Impact factor: 11.205

4.  Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.

Authors:  S Salomone; T Godfraind
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

5.  Calcium channels from Cyprinus carpio skeletal muscle.

Authors:  M Grabner; K Friedrich; H G Knaus; J Striessnig; F Scheffauer; R Staudinger; W J Koch; A Schwartz; H Glossmann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

6.  Biochemical evidence for a complex involving dihydropyridine receptor and ryanodine receptor in triad junctions of skeletal muscle.

Authors:  I Marty; M Robert; M Villaz; K De Jongh; Y Lai; W A Catterall; M Ronjat
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.